Non-small-cell lung cancer
Hendriks, L. E. L. Remon, J. Faivre-Finn, Corinne Garassino, M. C. Heymach, J. V. Kerr, K. M. Tan, D. S. W. Veronesi, G. Reck, M.
Hendriks, L. E. L.
Remon, J.
Faivre-Finn, Corinne
Garassino, M. C.
Heymach, J. V.
Kerr, K. M.
Tan, D. S. W.
Veronesi, G.
Reck, M.
Citations
Altmetric:
Abstract
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and radiotherapeutic techniques and a deeper biological understanding of NSCLC that has led to innovative systemic treatment options have improved the prognosis of patients with NSCLC. In non-metastatic NSCLC, the combination of various perioperative strategies and adjuvant immunotherapy in locally advanced disease seem to enhance cure rates. In metastatic NSCLC, the implementation of novel drugs might prolong disease control together with preserving quality of life. The further development of predictive clinical and genetic markers will be essential for the next steps in individualized treatment concepts.
Affiliation
Description
Date
2024
Publisher
Collections
Keywords
Type
Other
Citation
Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nature reviews Disease primers. 2024 Sep 26;10(1):71. PubMed PMID: 39327441. Epub 2024/09/27. eng.